These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28975571)

  • 1. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
    Pagano G; Yousaf T; Politis M
    Curr Neurol Neurosci Rep; 2017 Oct; 17(11):90. PubMed ID: 28975571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.
    Pagano G; Niccolini F; Politis M
    J Neural Transm (Vienna); 2018 Aug; 125(8):1217-1223. PubMed ID: 29264660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging of levodopa-induced dyskinesias.
    Niccolini F; Rocchi L; Politis M
    Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
    J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
    Niccolini F; Loane C; Politis M
    Eur J Neurol; 2014 May; 21(5):694-9, e39-43. PubMed ID: 24471508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
    Smith R; Wu K; Hart T; Loane C; Brooks DJ; Björklund A; Odin P; Piccini P; Politis M
    Neurobiol Aging; 2015 Apr; 36(4):1736-1742. PubMed ID: 25649022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
    Wang L; Wang M; Si Q; Yuan Y; Ma K; Gan C; Zhang K
    Parkinsonism Relat Disord; 2019 Oct; 67():36-41. PubMed ID: 31621605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced dyskinesias.
    Damier P
    Curr Opin Neurol; 2009 Aug; 22(4):394-9. PubMed ID: 19491677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Roussakis AA; Politis M; Towey D; Piccini P
    Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
    Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
    Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
    Carta M; Bezard E
    Neuroscience; 2011 Dec; 198():245-51. PubMed ID: 21840375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
    Piccini P; Weeks RA; Brooks DJ
    Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET studies and motor complications in Parkinson's disease.
    Brooks DJ
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
    Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroplasticity in levodopa-induced dyskinesias: An overview on pathophysiology and therapeutic targets.
    Bove F; Angeloni B; Sanginario P; Rossini PM; Calabresi P; Di Iorio R
    Prog Neurobiol; 2024 Jan; 232():102548. PubMed ID: 38040324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Fu JF; Matarazzo M; McKenzie J; Neilson N; Vafai N; Dinelle K; Felicio AC; McKeown MJ; Stoessl AJ; Sossi V
    Mov Disord; 2021 Feb; 36(2):389-397. PubMed ID: 33090574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
    Picconi B; De Leonibus E; Calabresi P
    J Neural Transm (Vienna); 2018 Aug; 125(8):1263-1271. PubMed ID: 29492662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.